News
MRNS
--
0.00%
--
Top Biotech Stocks for Q1 2022
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. ...
Investopedia · 1d ago
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RADNOR, Pa., January 14, 2022--Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire · 4d ago
SVB Leerink Maintains Outperform on Marinus Pharmaceuticals, Lowers Price Target to $30
SVB Leerink analyst Marc Goodman maintains Marinus Pharmaceuticals (NASDAQ:MRNS) with a Outperform and lowers the price target from $32 to $30.
Benzinga · 12/20/2021 09:54
Data shows extended benefit of Marinus epilepsy treatment ganaxolone up to a year
Data from an open-label extension of a phase 3 trial of Marinus Pharmaceuticals (MRNS -7.8%) ganaxolone for CDKL5 deficiency disorder ("CDD") showed the treatment led to a reduction in motor
Seekingalpha · 12/03/2021 17:31
Marinus Pharmaceuticals Announces New Clinical And Research Data To Be Presented At American Epilepsy Society Meeting On Dec. 6 At 1 p.m. EST
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced new clinical trial and research data
Benzinga · 12/03/2021 15:01
Recap: Marinus Pharmaceuticals Q3 Earnings
  Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 11/09/2021 13:11
BRIEF-Marinus Pharma Reports Third Quarter 2021 Financial Results
reuters.com · 11/09/2021 12:14
Marinus Pharmaceuticals Q3 EPS $(0.53) Beats $(0.73) Estimate, Sales $10.11M Up From $171.00K YoY
Marinus Pharmaceuticals (NASDAQ:MRNS) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.73) by 27.4 percent. This is a 3.92 percent decrease over losses of $(0.51) per share
Benzinga · 11/09/2021 12:10
Marinus Pharmaceuticals EPS beats by $0.12, beats on revenue
Marinus Pharmaceuticals (NASDAQ:MRNS): GAAP EPS of -$0.53 beats by $0.12. Revenue of $10.11M beats by $4.95M. Press Release
Seekingalpha · 11/09/2021 12:09
Marinus Pharmaceuticals Q3 2021 Earnings Preview
Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.65 (-27.5% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 11/08/2021 17:28
Notable earnings before Tuesday's open
ADT,AGEN,AGTC,ALLT,APRN,AUD,OTCPK:BAYZF,BHVN,BNTX,BSY,CAH,CANO,CCO,CEVA,CNCE,CORR,DCTH,DHI,DRNA,EBIX,ECOM,EGRX,EPZM,EXK,FOLD,GILT,GLNG,GOL,HAE,HAIN,HGV,HUYA,IGT,IIVI,INSW,ISEE,ITCI,KNDI,KPLT,MIDD,MLCO,MNTV,MRNS,MRSN,MSGE,OTCPK:NSANY,NSPR,NUWE,OCGN,OESX,OSG...
Seekingalpha · 11/08/2021 15:52
Michael Burry Stock Portfolio: 10 Newest Additions in 2021
In this article, we discuss the newest stocks in Michael Burry’s portfolio. You can skip our detailed analysis of Michael Burry’s hedge fund and its returns, and go directly to read Michael Burry Stock Portfolio: 5 Newest Additions in 2021. Michael Burry m...
Insider Monkey · 10/25/2021 12:38
BRIEF-Marinus Pharmaceuticals Joins The Loulou Foundation In Collaboration On Candid
reuters.com · 10/25/2021 12:29
Are Institutions Heavily Invested In Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Shares?
Every investor in Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) should be aware of the most powerful shareholder...
Simply Wall St. · 10/15/2021 13:56
Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event
RADNOR, Pa., October 05, 2021--Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event
Business Wire · 10/05/2021 11:30
BRIEF-FDA Accepts For Filing And Priority Review Marinus' NDA For Ganaxolone In CDKL5 Deficiency Disorder
reuters.com · 09/20/2021 11:43
FDA Grants Priority Review to Marinus' New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder
MT Newswires · 09/20/2021 08:54
Michael Burry is Loading Up on These 9 Stocks
In this article, we discuss the 9 stocks Michael Burry is loading up on. If you want to skip our detailed analysis of these stocks, go directly to Michael Burry is Loading Up on These 4 Stocks. There are very few investors who command sweeping attention on...
Insider Monkey · 09/14/2021 14:15
BRIEF-EMA Grants Marinus Pharmaceuticals Accelerated Assessment Of Ganaxolone
reuters.com · 08/26/2021 11:46
Webull provides a variety of real-time MRNS stock news. You can receive the latest news about Marinus Pharms through multiple platforms. This information may help you make smarter investment decisions.
About MRNS
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.